{"disease":{"id":"neuromyelitis-optica-spectrum-disorder","name":"neuromyelitis optica spectrum disorder"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06643858","title":"Normal Chinese Lifespan Brain Charts Initiative (NCLBCI)","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":10000,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false},{"nct_id":"NCT07032337","title":"Efficacy and Safety of Conventional Immunosuppressant Therapies in Elderly Patients With Neuromyelitis Optica Spectrum Disorder","phase":"","overall_status":"COMPLETED","enrollment_count":2985,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT03900221","title":"French Registry for Monitoring Pregnancies for Multiple Sclerosis","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT05204459","title":"MS-ResearchBiomarkerS","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Cedars-Sinai Medical Center","has_results":false},{"nct_id":"NCT07164924","title":"Evaluation of the Impact of Multiple Sclerosis and Its Treatments on Women Fertility","phase":"","overall_status":"COMPLETED","enrollment_count":800,"lead_sponsor_name":"University Hospital, Clermont-Ferrand","has_results":false},{"nct_id":"NCT07202494","title":"Integrating Metabolism, Connectivity, and Mesoscale Imaging at Ultra-high Field to Decipher Mechanisms of Resilience and Neurodegeneration in Neurological Diseases and Healthy Aging","phase":"","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"Assistance Publique Hopitaux De Marseille","has_results":false},{"nct_id":"NCT05017142","title":"Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"University of Bern","has_results":false},{"nct_id":"NCT06541626","title":"Sun Yat-Sen Cohort of CNS Idiopathic Inflammatory Demyelinating Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT02200770","title":"N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":231,"lead_sponsor_name":"MedImmune LLC","has_results":true},{"nct_id":"NCT04388072","title":"An Diagnostic Cohort on AQP4-Immunoglobulin G Detection Kit","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"First Affiliated Hospital of Fujian Medical University","has_results":false},{"nct_id":"NCT07410039","title":"Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT04101058","title":"Treatment Response Among Chinese Neuromyelitis Optica Spectrum Disorders","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Third Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT05605951","title":"Acute Optic Neuritis Network: an International Study That Invesitages Subjects With a First-ever Episode of Acute Inflammation of the Optic Nerve","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecul","has_results":false},{"nct_id":"NCT07420296","title":"Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":198,"lead_sponsor_name":"Tianjin Medical University General Hospital","has_results":false},{"nct_id":"NCT03330418","title":"A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":178,"lead_sponsor_name":"RemeGen Co., Ltd.","has_results":false},{"nct_id":"NCT07132398","title":"Slow vs. Rapid Glucocorticoids Tapering With Inebilizumab in NMOSD","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":170,"lead_sponsor_name":"Tianjin Medical University General Hospital","has_results":false},{"nct_id":"NCT06763848","title":"Protein A immuNoaDsorption for the Treatment of Acute Episodes of Neuromyelitis Optica Spectrum Disorder","phase":"NA","overall_status":"RECRUITING","enrollment_count":144,"lead_sponsor_name":"Third Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT04064944","title":"Comparison of the Efficacy and Safety of Immunoadsorption and Plasma Exchange for Acute Attack of Refractory Neuromyelitis Optica Spectrum Disorders","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":144,"lead_sponsor_name":"Third Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT01892345","title":"A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":143,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT05403138","title":"Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":135,"lead_sponsor_name":"Tianjin Medical University General Hospital","has_results":false},{"nct_id":"NCT06413654","title":"A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Shanghai Jiaolian Drug Research and Development Co., Ltd","has_results":false},{"nct_id":"NCT05966467","title":"Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies","phase":"","overall_status":"RECRUITING","enrollment_count":122,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT04660539","title":"A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":119,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT02003144","title":"An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":119,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03350633","title":"Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":118,"lead_sponsor_name":"Tianjin Medical University General Hospital","has_results":false},{"nct_id":"NCT06557174","title":"A Study to Evaluate IMC-002 in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":116,"lead_sponsor_name":"ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.","has_results":false},{"nct_id":"NCT04131764","title":"Diagnosis of ON With or Without MS or NMOSD","phase":"","overall_status":"TERMINATED","enrollment_count":112,"lead_sponsor_name":"Jagannadha R Avasarala","has_results":false},{"nct_id":"NCT07184840","title":"Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":110,"lead_sponsor_name":"Tianjin Medical University General Hospital","has_results":false},{"nct_id":"NCT07247292","title":"Epidemiological Study of Treatment Approaches on AQP4-IgG Positive NMOSD in Russia","phase":"","overall_status":"SUSPENDED","enrollment_count":100,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03766347","title":"Pediatric NMOSD Observational Study","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06829524","title":"HANDLE-a Real World Study on Satralizumab in NMOSD","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT02073279","title":"Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":95,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT03819413","title":"Clinical Patterns of Neuromyelitis Optica Spectrum Disorders in Assiut University Hospital","phase":"","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT02028884","title":"Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":85,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT06068829","title":"Inebilizumab and Rituximab in Neuromyelitis Optica Spectrum Disorders","phase":"","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Feng Jinzhou","has_results":false},{"nct_id":"NCT06312644","title":"Study of Ultomiris® (Ravulizumab) Safety in Pregnancy","phase":"","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT06620809","title":"The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":69,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT06497374","title":"FcRn Antagonists (Efgartigimod) for Acute NMOSD Attack","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":63,"lead_sponsor_name":"Tianjin Medical University General Hospital","has_results":false},{"nct_id":"NCT05909761","title":"Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy","phase":"","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT04201262","title":"An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":58,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT06865274","title":"Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Anti-oligodendrocyte Myelin Protein Antibody Disease, and Multiple Sclerosis.","phase":"NA","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT05891379","title":"Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Xuanwu Hospital, Beijing","has_results":false},{"nct_id":"NCT07526298","title":"Anticipating Irreversible Disability in Neuromyelitis Optica Spectrum Disorder: a Study to Assess Disease Activity in Apparently Stable Patients","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT05551598","title":"Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":46,"lead_sponsor_name":"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.","has_results":false},{"nct_id":"NCT06869278","title":"A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":37,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT04561557","title":"Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT06697535","title":"A Study to Evaluate the Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"Guangzhou JOYO Pharma Co., Ltd","has_results":false},{"nct_id":"NCT05414487","title":"Effects of Ofatumumab Treatment on Immune Cells and Meningeal Lymphatic Drainage in Patients With Demyelinating Diseases","phase":"","overall_status":"UNKNOWN","enrollment_count":34,"lead_sponsor_name":"Tianjin Medical University General Hospital","has_results":false},{"nct_id":"NCT06212245","title":"A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":33,"lead_sponsor_name":"Hansoh BioMedical R&D Company","has_results":false},{"nct_id":"NCT06180278","title":"Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":32,"lead_sponsor_name":"Amgen","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}